Arena Pharmaceuticals to Announce First Quarter 2005 Financial Results on Tuesday, April 26, 2005, and to Host Conference Call and Webcast on Wednesday, April 27, 2005
SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the company will release its financial
results for the first quarter of 2005, after the NASDAQ National Market closes
on Tuesday, April 26, 2005. Arena also announced today that Jack Lief,
President and Chief Executive Officer, will host a conference call to discuss
the financial results from the first quarter of 2005 and to provide a
corporate update. The call will take place on Wednesday, April 27, 2005, at
9:00 a.m. EDT (6:00 a.m. PDT).
The conference call may be accessed by dialing 888-396-2369 for domestic
callers and 617-847-8710 for international callers. Please specify to the
operator that you would like to join the "Arena First Quarter Earnings Call."
The conference call will be webcast live under the investor relations section
of Arena's website at http://www.arenapharm.com , and will be archived there
for 30 days following the call. Please connect to Arena's website several
minutes prior to the start of the conference call to ensure adequate time for
any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focusing on the
discovery, development and commercialization of small molecule drugs in four
major therapeutic areas: metabolic, cardiovascular, inflammatory and central
nervous system diseases. Arena is developing a broad pipeline of compounds
that act on an important class of drug targets called G protein-coupled
receptors, or GPCRs, using its proprietary technologies, including CART
(Constitutively Activated Receptor Technology) and Melanophore. Arena's most
advanced clinical compound, APD356, a selective 5-HT2C serotonin receptor
agonist for the treatment of obesity, is in a Phase 2 clinical trial. Arena is
also conducting a Phase 1 clinical trial on APD125, a compound with a novel
mechanism of action (a selective 5-HT2A receptor antagonist) for the treatment
of insomnia. Arena has research collaborations with Ortho-McNeil
Pharmaceutical, Inc., Merck & Co., Inc. and other companies for products in a
number of different indications.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, technologies,
preclinical and clinical programs, and ability to develop compounds. For such
statements, Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, the timing, success and cost of Arena's research, out-licensing endeavors
and clinical studies, Arena's ability to obtain additional financing, and the
timing and receipt of payments and fees, if any, from Arena's collaborators,
including Ortho-McNeil and Merck. Additional factors that could cause actual
results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.
NOTE: Arena Pharmaceuticals® and Arena® are registered service marks
of the company. CART is an unregistered service mark of the company.
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO, or David Walsey, Director,
Corporate Communications, both of Arena Pharmaceuticals, Inc.,
+1-858-453-7200; or Media & Investor Relations, Susan Neath of
Atkins + Associates, +1-858-527-3486, for Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com